Concord Drugs Standalone December 2023 Net Sales at Rs 12.62 crore, down 6.67% Y-o-Y
February 16, 2024 / 11:45 IST
Reported Standalone quarterly numbers for Concord Drugs are: Net Sales at Rs 12.62 crore in December 2023 down 6.67% from Rs. 13.53 crore in December 2022. Quarterly Net Loss at Rs. 0.24 crore in December 2023 down 152.71% from Rs. 0.45 crore in December 2022. EBITDA stands at Rs. 0.56 crore in December 2023 down 61.38% from Rs. 1.45 crore in December 2022. Concord Drugs shares closed at 41.84 on February 15, 2024 (BSE) and has given 33.12% returns over the last 6 months and 39.23% over the last 12 months.
| Concord Drugs | | Standalone Quarterly Results | in Rs. Cr. |
|
Story continues below Advertisement
| Dec'23 | Sep'23 | Dec'22 | | Net Sales/Income from operations | 12.62 | 7.38 | 13.53 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 12.62 | 7.38 | 13.53 | | EXPENDITURE | | Consumption of Raw Materials | 10.44 | 4.74 | 10.03 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | 0.01 | -0.45 | -0.32 | | Power & Fuel | -- | -- | -- | | Employees Cost | 1.20 | 1.28 | 1.31 | | Depreciation | 0.38 | 0.38 | 0.38 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 0.41 | 0.29 | 1.07 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 0.18 | 1.14 | 1.06 | | Other Income | -- | 0.01 | 0.00 | | P/L Before Int., Excpt. Items & Tax | 0.18 | 1.15 | 1.07 | | Interest | 0.43 | 0.39 | 0.45 | | P/L Before Exceptional Items & Tax | -0.26 | 0.76 | 0.62 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -0.26 | 0.76 | 0.62 | | Tax | -0.02 | 0.24 | 0.16 | | P/L After Tax from Ordinary Activities | -0.24 | 0.53 | 0.45 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -0.24 | 0.53 | 0.45 | | Equity Share Capital | 10.00 | 9.32 | 8.74 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -0.24 | 0.56 | 0.52 | | Diluted EPS | -0.24 | 0.56 | 0.52 | | EPS After Extra Ordinary | | Basic EPS | -0.24 | 0.56 | 0.52 | | Diluted EPS | -0.24 | 0.56 | 0.52 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
